Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00298285 · ClinicalTrials.gov registry record · Phase 4
ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement
A Phase 4 study of Mechanical Valve Replacement and Warfarin Therapy, sponsored by The Cleveland Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT00298285 is a Phase 4 study of Mechanical Valve Replacement and Warfarin Therapy that has completed, run by The Cleveland Clinic. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00298285, a Phase 4 study of Mechanical Valve Replacement and Warfarin Therapy, has completed, sponsored by The Cleveland Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary aim is to determine the rate of major bleeding and blood clots when using enoxaparin as a bridge to oral blood thinning medication in patients who have undergone mechanical valve replacement.
Conditions Studied
Interventions
- DRUG enoxaparin
Study Locations (1)
Ohio
- Cleveland Clinic - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Est. Completion | 2006-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00298285
The ClinicalTrials.gov registry entry for NCT00298285 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Mechanical Valve Replacement appearing as the primary indexed condition, and to 1 intervention - of which enoxaparin is the first listed.
NCT00298285 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT00298285 about?
NCT00298285 is a clinical study titled "ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement". The primary aim is to determine the rate of major bleeding and blood clots when using enoxaparin as a bridge to oral blood thinning medication in patients who have undergone mechanical valve replacement.
What is the current status of trial NCT00298285?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. Estimated completion is 2006-10.
What conditions does trial NCT00298285 study?
This clinical trial studies the following conditions: Mechanical Valve Replacement, Warfarin Therapy.
What interventions are being tested in trial NCT00298285?
The interventions under investigation include: enoxaparin (DRUG).
Who is sponsoring clinical trial NCT00298285?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00298285 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.